Drugs / Daily hGH
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04326374 Comparator | Dec 2019 → Apr 2022 | anterior pituitary gland disorder, pituitary deficiency | Visen Pharmaceuticals (Shanghai) Co., Ltd. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daily hGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04326374 ↗ |
| Modality | Protein / enzyme biologic | “human growth hormone (hGH)” NCT04326374 ↗ |
| Route | Subcutaneous | “Once daily subcutaneous injection” NCT04326374 ↗ |